The results revealed that the serum DHA levels in the TACC3-high HCC patients were markedly lower than those in the TACC3-low patients (Supplementary Fig. 6f), which aligns with our targeted metabolomics data. Here, TACC3 is linked to hepatocellular carcinoma.